Your AI-Trained Oncology Knowledge Connection!
A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.
A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.
Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.
The use of 68Ga-FAP-2286 PET imaging may improve treatment selection and response assessment in patients with bladder cancer, according to findings from a pilot study evaluating the diagnostic performance of this imaging technology.
Michael Basin, MD, discusses how the pharmacological inhibition of the molecular chaperone Hsp70 overcomes belzutifan resistance in clear cell renal cell carcinoma.
Andrew Katims, MD, MPH, discusses the utility of a circulating tumor DNA assay (MSK-ACCESS) in patients with node-positive muscle-invasive bladder cancer.
The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.
Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.
Reduced doses of apalutamide did not significantly decrease rates of skin-related adverse effects vs full-dose apalutamide in patients with advanced prostate cancer.
Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.
The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.
A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.
Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.
Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the clinical implications for data from the combination of tremelimumab plus durvalumab and chemotherapy in metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.
Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.
The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.
Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.
Jayesh Desai, MBBS, FRACP, discusses efficacy data for the combination of divarasib plus cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation from a phase 1B study.
Whole-exome sequencing successfully identified genetic conditions in patients who may have been missed by clinical guidelines.
John Michael "JM" Bryant, MD, discusses the combination of nivolumab with standard of care in the management of patients with prostate cancer, detailing the results of the interim analysis of the phase 2 trial.
A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.
The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.
Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.
Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.
The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.
Lifirafenib plus mirdametinib produced a tolerable safety profile and antitumor activity in patients with BRAF- or KRAS-mutant advanced or refractory solid tumors.
LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.
